Kinetics of endogenous leukotriene B4 and E4 production following injection of the chemotactic peptide FMLP in the rabbit

被引:4
作者
Celardo, A [1 ]
Dell'Elba, G [1 ]
Manarini, S [1 ]
Evangelista, V [1 ]
de Gaetano, G [1 ]
Cerletti, C [1 ]
机构
[1] Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Vasc Med & Pharmacol G Bizzozero, Lab Platelet & Leukocyte Pharmacol, I-66030 Santa Maria Imbaro, Italy
来源
PROSTAGLANDINS & OTHER LIPID MEDIATORS | 1997年 / 54卷 / 04期
关键词
leukotrienes; peptidyl leukotrienes; chemotactic agent FMLP; kinetics of endogenous leukotrienes; rabbit model of inflammation;
D O I
10.1016/S0090-6980(97)00146-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The kinetic profiles of leukotriene B-4 (LTB4) and E-4 (LTE4) after intravenous administration (30 nmol/kg) of the inflammatory peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) were evaluated in male rabbits. LTB4 and LTE4 reached the maximal concentration of 84.2 +/- 60.0 and 162.2 +/- 51.4 nmol/L (mean +/- s.d.), at 2 and 5 min, respectively. The first elimination phase for LTB4 and LTE4, after FMLP administration, showed an apparent half-life of 24.6 +/- 6.7 and 36.9 +/- 13.0 min, respectively. The area under the blood concentration-time curve (AUC, nmol min/L) of LTB4 and LTE4 was 2178 +/- 1591 and 7627 +/- 3052, respectively. LTE4 and N-ac-LTE4 were the major components excreted in the urine, mostly in the first time interval (0-12 h) of urinary collection after FMLP treatment; 11-trans-LTE4 was recovered in the second interval (12-24 h). Two other more polar compounds, potential metabolites, were recovered in the first interval of urine collection. Knowledge of the kinetic characteristics of endogenously produced leukotrienes may be useful in understanding the role of these eicosanoids in inflammatory and thrombotic disease, as well as in evaluating the efficacy of drugs designed to modulate their production and effect.
引用
收藏
页码:699 / 711
页数:13
相关论文
共 26 条
  • [1] BALL HA, 1987, BIOCHEM BIOPH RES CO, V14, P664
  • [2] THE RELEASE OF A LEUKOTRIENE D4-LIKE SUBSTANCE FOLLOWING MYOCARDIAL-INFARCTION IN RABBITS
    BARST, S
    MULLANE, K
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 114 (03) : 383 - 387
  • [3] BEREND N, 1985, AGENTS ACTIONS, V17, P466
  • [4] BOUKILI MA, 1985, BRIT J PHARMACOL, V89, P349
  • [5] INCREASED URINARY LEUKOTRIENE EXCRETION IN PATIENTS WITH CARDIAC ISCHEMIA - INVIVO EVIDENCE FOR 5-LIPOXYGENASE ACTIVATION
    CARRY, M
    KORLEY, V
    WILLERSON, JT
    WEIGELT, L
    FORDHUTCHINSON, AW
    TAGARI, P
    [J]. CIRCULATION, 1992, 85 (01) : 230 - 236
  • [6] SIMULTANEOUS DETERMINATION OF LEUKOTRIENES B(4) AND E(4) IN WHOLE-BLOOD AND OF LEUKOTRIENE E(4) IN URINE OF RABBIT BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    CELARDO, A
    DELLELBA, G
    ELTANTAWY, ZM
    EVANGELISTA, V
    CERLETTI, C
    [J]. JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 658 (02): : 261 - 269
  • [7] DENZLINGER C, 1986, J BIOL CHEM, V261, P5601
  • [8] LEUKOTRIENES AS MEDIATORS IN TISSUE TRAUMA
    DENZLINGER, C
    RAPP, S
    HAGMANN, W
    KEPPLER, D
    [J]. SCIENCE, 1985, 230 (4723) : 330 - 332
  • [9] EVANGELISTA V, 1995, THROMB HAEMOSTASIS, V73, P1085
  • [10] Gibaldi M. P., 1982, PHARMACOKINETICS